高校男教工脂肪肝与血脂血糖相关性调查分析

目的 调查高校男教工脂肪肝、血脂、血糖患病情况,并初步探讨脂肪肝与血脂、血糖的关系.方法 以郑州某高校23～75岁男教工1 004例为研究对象,统计分析其体检中脂肪肝、血脂、血糖情况.结果 脂肪肝患病率为17.33%,高血脂者、高血糖者的脂肪肝检出率显著高于血脂、血糖正常者.结论 脂肪肝是由多种疾病和原因引起的疾病,高血脂是引起脂肪肝的重要原因之一.     

女性脂肪肝患者的超声诊断分析

目的探讨超声在女性脂肪肝患者诊断中的应用价值及女性脂肪肝患者与年龄、生活习惯、血糖、血脂等发病相关因素的关系。方法回顾性分析唐山市协和医院64例女性患者的脂肪肝发病情况,并比较分析患者的年龄、生活习惯、血糖、血脂与脂肪肝发病率之间的关系。结果 64例女性脂肪肝患者,脂肪肝与年龄的关系:各年龄组(20～30、31～40、41～50、51～60、61～70岁)的患者分别为4例(6.3%)、7例(11.0%)、19例(29.7%)、26例(40.6%)、8例(12.5%),50～60年龄组患病率最高。脂肪肝与生活习惯的关系:机关工作人员27例(42.2%),企业职工21例(32.8%),无业人群16例(25.0%)。脂肪肝与血糖、血脂的关系:血糖、血脂正常3例(4.7%),单纯血糖升高11例(17.2%),单纯血脂升高33例(51.6%),血糖、血脂均升高17例(26.6%)。结论女性脂肪肝患者在更年期前后发病较高,女性脂肪肝发病与血脂、血糖升高及生活习惯密切相关。B超可作为脂肪肝的首选检查方法。     

超声体检对脂肪肝疾病的诊断价值

目的 探讨超声体检对脂肪肝疾病的应用价值.方法 对本市2009年参加体检的不同人群8612名男女进行体检,超声诊断医师按照脂肪肝统一诊断标准经腹部彩色多普勒超声检查做出脂肪肝诊断,并分析脂肪肝患病相关因素.结果 脂肪肝发病率27.52%.其中,男性36.86%,女性12.53%;机关工作人员脂肪肝患病率40.3%,明显高于企业职工的22.0%及普通无业人群的12.9%.结论 脂肪肝的患病程度与患者血液中血脂的高低有直接关系,而生活环境、习惯与血液中血脂的高低有着密切关系.超声诊断可作为对脂肪肝诊断、随访、检测的无创、便捷的有效手段.     

脂肪肝与血糖、血脂及肝功能的关系研究

目的探讨脂肪肝与血糖血脂及肝功能的关系。方法对我市参加体检的公务人员3168例的B超、血糖、血脂及肝功能检测结果进行统计分析。结果(1)在机关公务人员中脂肪肝的发病率为19.2%,其中,男性(21.2%)明显高于女性(8.5%),在肥胖人员中,脂肪肝发病率(64.8%)明显高于非肥胖者(11.8%);(2)脂肪肝组的血糖(GLU)、血清甘油三脂(TG)、胆固醇(TC)及肝功能异常比例分别为15.8%、35.86%、30.26%和51.64%,均明显高于非脂肪肝组;(3)脂肪肝患者中,肥胖者TG及谷丙转氨酶(ALT)水平明显高于非肥胖者(P<0.01),TC比较P<0.05,而GLU及谷草转氨酶(AST)两组比较无明显差异。结论机关公务人员中脂肪肝发病率较高,脂肪肝人群中存在明显的血糖、血脂的代谢紊乱及肝功能异常,肥胖者则更明显。     

职工脂肪肝患病情况及原因分析

目的了解某单位脂肪肝患病情况及其与体重指数、血压、血糖、血脂的关系。方法对北京市某单位职工进行体检,对其结果进行统计学分析。结果 440名职工中超重及肥胖总检出率为35.0%,随年龄增长BMI随之增长,脂肪肝的检出率增加,其组间差异有统计学意义(P<0.01);脂肪肝组中超重及肥胖、空腹血糖增高、血脂异常及高血压病患病率均显著高于非脂肪肝组,其组间差异有统计学意义(P<0.01)。结论脂肪肝的形成与血糖增高、血脂异常及高血压病关系密切;膳食不合理、缺乏锻炼、超重及肥胖应是主要原因,应加强职工健康理念教育,改变其不良的生活方式。     

脂肪肝声像图表现与糖、脂代谢关系探讨

目的探讨脂肪肝的超声影像与糖、脂代谢的关系。方法选取215例脂肪肝患者作为脂肪肝组,另选取无脂肪肝的健康人226例作为对照组。比较2组血糖、血脂及体质量指数。结果 215例脂肪肝患者,均匀性脂肪肝198例,非均匀性脂肪肝17例。脂肪肝组血脂、血糖及体质量指数均明显高于对照组,差异均有统计学意义(P<0.01)。脂肪肝组中,超质量164例占76.3%,血脂升高158例占73.5%,血糖升高84例占39.1%。结论脂肪肝并非一独立因素疾病,以体内代谢紊乱为主要表现,尤与糖、脂代谢有关。     

B超及血脂分析在诊断脂肪肝患者中的价值

目的了解脂肪肝患者血脂指标的变化及B超在脂肪肝诊断中的价值。方法对体检者在常规B超检查的同时进行血糖、血脂及体质量指数检测。结果在1522例受检者中发现脂肪肝149例(9.78%)。脂肪肝患者按其程度分为轻、中、重度,按其声像图特点分为弥漫型、非均匀型及局限型,脂肪肝患者血糖、血脂及体质量指数均有不同程度升高。结论血脂代谢异常者行B超检查更能及时发现脂肪肝。     

脂肪肝与血糖血脂的相关性临床研究

目的探讨脂肪肝的发生与血糖血脂的含量关系的探讨。方法筛选本院2007年体检人员对经B超检出的315名脂肪肝和B超检查正常的271名体检者的临床资料,测定研究对象的空腹血糖血脂的水平。结果脂肪肝的发生与血脂水平呈正相关,血糖异常患者换脂肪肝的发生率明显升高,脂肪肝患者的血糖血脂水平与非脂肪肝的人群的血糖血脂水平的有显著的统计学差异(P<0.01)。结论脂肪肝的人群与血糖血脂的升高密切相关,防治脂肪肝要采取综合措施。     

脂肪肝声像图表现与糖、脂代谢关系探讨

目的 探讨脂肪肝的超声影像与糖、脂代谢的关系.方法 选取215例脂肪肝患者作为脂肪肝组,另选取无脂肪肝的健康人226例作为对照组.比较2组血糖、血脂及体质量指数.结果 215例脂肪肝患者,均匀性脂肪肝198例,非均匀性脂肪肝17例.脂肪肝组血脂、血糖及体质量指数均明显高于对照组,差异均有统计学意义(P＜0.01).脂肪肝组中,超质量164例占76.3%,血脂升高158例占73.5%,血糖升高84例占39.1%.结论 脂肪肝并非一独立因素疾病,以体内代谢紊乱为主要表现,尤与糖、脂代谢有关.     

脂肪肝的影响因素分析

目的探讨脂肪肝与性别、年龄、血脂、血糖的关系。方法采用整群抽样方法抽取1570人进行的肝胆超声检查及血脂、血糖的化验,然后进行统计学处理。结果本次调查群体的脂肪肝患病率为8．79％,男性、中老年、高血脂、高血糖组的脂肪肝发病率显著高于女性、青年、血脂正常、血糖正常组。结论脂肪肝与性别、年龄、血脂、血糖有着密切关系。     

青年人群中非酒精性脂肪肝患者糖代谢状况的评价

目的:探讨青年人群中非酒精性脂肪肝患者的糖代谢情况及其高危因素分析。方法:对260例青年人非酒精性脂肪肝患者进行口服葡萄糖耐量试验(OGTT),根据OGTT结果分为糖耐量正常(NGT)、空腹血糖受损(IFG)、糖耐量减退(IGT)和糖尿病(DM)4组,分析各组的发病率,对各组的血脂(TG、TC、HDL、LDL)、体重指数、腰围、胰岛素抵抗(HOMA-IR)、β细胞功能(HOMA-β)、胰岛素敏感性指数(ISI)、空腹及餐后2h胰岛素等进行比较。结果:青年人非酒精性脂肪肝患者近2/3有糖代谢异常,发病率非常高,但知晓率很低;随糖代谢异常的加重,脂肪肝患者的体重指数、腰围呈上升趋势,IFG和NGT组间比较无差异(P>0.05),IGT或DM组与NGT组比较差异有显著性(P<0.05);血脂异常也越加明显,TG、TC、LDL呈上升趋势,HDL则下降;IGT组HOMA-IR明显升高(P<0.01),与DM组比较无差异;IGT组HOMA-β细胞功能升高,与其它3组间比较无差异,DM组和IGT组ISI下降。结论:青年人群中非酒精性脂肪肝患者存在明显的糖耐量异常,随着糖耐量异常的加重,其他代谢异常也恶化。有必要对青年人非酒精性脂肪肝患者进行OGTT,做到早期发现早期干预,预防糖尿病对心、脑、肾等脏器损害所致并发症。     

驻京某部科技干部脂肪肝发病率及相关因素分析

目的调查驻京某部科技干部脂肪肝发病率,探讨脂肪肝与血脂、体重、血糖、性别和年龄之间的关系。方法对1986例受检者进行体检,采用B超诊断脂肪肝,分轻度和中度以上两组,测定血脂、血糖及体重指数（BMI）,分组比较脂肪肝发病率与上述因素的关系。结果（1）脂肪肝的发生与三酰甘油升高、肥胖和血糖升高有明显关系,在中度以上尤为明显（P〈0．01）,与胆固醇的升高无明显关系（P〉0．05）。（2）脂肪肝发病率男性高于女性（P〈0．01）,且中度以上尤为明显（P〈0．01）。（3）脂肪肝的发病率与年龄有关,51～60岁明显高于其他年龄组（P〈0．01）。结论驻京某部科技干部脂肪肝发病率与甘油三酯升高、肥胖、高血糖、性别和年龄明显相关。     

老年人非酒精性脂肪性肝病与血脂血糖水平及体重指数的关系

目的探讨老年人非酒精性脂肪性肝病(NAFLD)与血脂血糖水平、体重指数等指标的关系。方法298例老年人按非酒精性脂肪性肝病诊断标准分为脂肪肝组(114例)和非脂肪肝组(184例),观察临床表现,检测血脂、血糖、体重指数、肝功能等指标并进行分析。结果脂肪肝组血脂、血糖水平、体重指数明显增高,和非脂肪肝组比较差异有显著性(P相似文献   

肾移植术后高脂血症的影响因素研究

目的：研究肾移患者植术后高脂血症的影响因素。方法：回顾分析826例肾移植患者中出现高脂血症的267例患者,调查术后时间、环孢素（CsA）全血浓度对患者移植术后血脂影响,及高血脂对患者肝、肾功能和血糖的影响。结果：肾移植术后0～3个月、4～6个月、7—12个月、1—2年高脂血症发生率分别为6．8％、7．0％、7．6％、10．9％,患者首次血脂异常时的总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL）水平与CsA全血浓度呈相关趋势。肾移植患者出现高血脂时,其血肌酐（SCr）和血糖（Glu）也明显升高,服药降低血脂后,SCr和Glu明显下降至血脂异常前水平（P〈0．05）,而未服用调脂药仅控制饮食的患者,首次血脂异常后3个月的Glu和SCr水平继续升高,显著高于首次血脂异常时的水平（P〈0．05）。结论：CsA对肾移植患者术后血脂的影响呈一定的浓度依赖性;术后1年内是肾移植受者高血脂症高发期。高血脂可明显影响移植肾功能,同时使患者血糖升高,应密切监测血脂变化．及时降脂治疗。     

Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases

Lipids are essential components of biological membranes, fuel molecules and metabolic regulators that control cellular functions, metabolism and homeostasis. The liver plays a central role in regulating lipid metabolism and whole body lipid homeostasis. Sterols, bile acids and fatty acids are the endogenous ligands of the liver orphan receptor, farnesoid X receptor, peroxisome proliferator-activated receptor, vitamin D receptor, constitutive androstane receptor and pregnane X receptor. These metabolic receptors coordinately regulate lipid, glucose, energy and drug metabolism. Alteration of lipid homeostasis causes dyslipidemia, which is a major risk factor contributing to atherosclerotic cardiovascular diseases, diabetes, obesity and liver diseases. Advances in the understanding of the mechanisms of nuclear receptor regulation of lipid homeostasis have provided an opportunity to investigate potential therapeutic drugs targeted to nuclear receptors. This could be useful for the treatment of diabetes, and cardiovascular and chronic liver diseases.     

Crocetin improves the insulin resistance induced by high-fat diet in rats

BACKGROUND AND PURPOSE: The amelioration of insulin resistance by treatment with crocetin is closely related to the hypolipidaemic effect. The present study is designed to clarify the insulin-sensitizing mechanism of crocetin by elucidating the mechanism of regulation of lipid metabolism by crocetin. EXPERIMENTAL APPROACH: Rats given a high-fat diet were treated with crocetin for 6 weeks before hyperinsulinaemic-euglycaemic clamp. 14C-palmitate was used as tracer to track the fate of non-esterified fatty acids or as substrate to measure beta-oxidation rate. Triglyceride clearance in plasma and lipoprotein lipase activity in tissues were tested. Content of lipids in plasma and tissues was determined. Real-time PCR was used to assay the level of mRNA from genes involved in non-esterified fatty acid and triglyceride uptake and oxidation. KEY RESULTS: Crocetin prevented high-fat-diet induced insulin resistance (increased clamp glucose infusion rate), raised hepatic non-esterified fatty acid uptake and oxidation, accelerated triglyceride clearance in plasma, enhanced lipoprotein lipase activity in liver, and reduced the accumulation of detrimental lipids (DAG and long-chain acyl CoA) in liver and muscle. Genes involved in hepatic lipid metabolism which are regulated by peroxisome proliferator-activated receptor-alpha, were modulated to accelerate lipid uptake and oxidation. CONCLUSIONS AND IMPLICATIONS: Through regulating genes involved in lipid metabolism, crocetin accelerated hepatic uptake and oxidation of non-esterified fatty acid and triglyceride, and reduced lipid availability to muscle, thus decreasing lipid accumulation in muscle and liver, and consequently improving sensitivity to insulin.     

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease

BACKGROUND: Non-alcoholic fatty liver disease is prevalent in affluent countries and is strongly associated with metabolic syndrome. AIM: To study the prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. METHODS: 73 consecutive patients with biopsy-proven non-alcoholic fatty liver disease and no history of diabetes underwent comprehensive metabolic screening. Diagnosis of diabetes and impaired glucose regulation was based on the 2006 American Diabetes Association criteria. RESULTS: The prevalence of undiagnosed diabetes and impaired glucose tolerance in non-alcoholic fatty liver disease patients was 33% and 29%, respectively. Among patients with 2-h plasma glucose above 7.8 mm, 47% had normal fasting glucose (below 5.6 mm). Impaired glucose tolerance was more common in patients with non-alcoholic steatohepatitis than those with simple hepatic steatosis (P = 0.036), and 2-h plasma glucose correlated with fibrosis stage (Spearman coefficient: 0.25, P = 0.046). In a binary logistic regression analysis, high fasting glucose and low high-density lipoprotein cholesterol were independent factors associated with diabetes. Nevertheless, if oral glucose tolerance test was only performed in non-alcoholic fatty liver disease patients with impaired fasting glucose, 20.8% of diabetes cases would be missed. CONCLUSIONS: Isolated postchallenge hyperglycaemia is common among Chinese non-alcoholic fatty liver disease patients without history of diabetes. It is associated with histological severe disease, and cannot be accurately predicted by any fasting glucose cut-off.     

Replacing smoking with vaping during pregnancy: Impacts on metabolic health in mice

Smoking is a significant risk factor for the development of metabolic diseases. Due to social pressures to quit smoking, many pregnant women are vaping as an alternative nicotine source. However, the metabolic consequences of replacing tobacco cigarettes with e-cigarettes during pregnancy are unknown. Therefore, in the mothers and their offspring, we investigated the metabolic and hepatic impacts of replacing cigarette smoke with e-vapour during pregnancy. Female BALB/c mice were either air-exposed or cigarette smoke-exposed (SE) from six weeks before pregnancy until lactation. At mating, a subset of the SE mice were instead exposed to e-vapour. Markers of glucose and lipid metabolism were measured in the livers and plasma, from the mothers and their male offspring (13 weeks). In the SE mothers, plasma insulin levels were reduced, leading to downstream increases in hepatic gluconeogenesis and plasma non-esterified fatty acids (NEFA). In the e-vapour replacement mothers, these changes were not as significant. In the SE offspring, there was impaired glucose tolerance, and increased plasma NEFA and liver triglyceride concentrations. E-vapour replacement restored lipid homeostasis but did not improve glucose tolerance. Therefore, in a murine model, low dose e-cigarette replacement during pregnancy is less toxic than cigarette smoke.     

Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells

Accumulation of visceral fat induces various symptoms of metabolic syndrome such as insulin resistance and abnormal glucose/lipid metabolism and eventually leads to the onset of ischemic cerebrovascular diseases. Geniposide, which is iridoid glycoside from the fruit of Gardenia jasminoides ELLIS, is recognized as being useful against hyperlipidemia and fatty liver. In order to clarify the effect of geniposide on metabolic disease-based visceral fat accumulation and the relevant molecular mechanism, experiments were performed in spontaneously obese Type 2 diabetic TSOD mice and the free fatty acid-treated HepG2 cells. In the TSOD mice, geniposide showed suppression of body weight and visceral fat accumulation, alleviation of abnormal lipid metabolism and suppression of intrahepatic lipid accumulation. In addition, geniposide alleviated abnormal glucose tolerance and hyperinsulinemia, suggesting that geniposide has an insulin resistance-alleviating effect. Next, in order to investigate the direct effect of geniposide on the liver, the effect on the free fatty acid-treated HepG2 fatty liver model was investigated using genipin, which is the aglycone portion of geniposide. Genipin suppressed the intracellular lipid accumulation caused by the free fatty acid treatment and also significantly increased the intracellular expression of a fatty acid oxidation-related gene (peroxisomal proliferator-activated receptor: PPARα). From these results, it was confirmed that geniposide has an anti-obesity effect, an insulin resistance-alleviating effect and an abnormal lipid metabolism-alleviating effect, and the metabolite genipin shows a direct effect on the liver, inducing expression of a lipid metabolism-related gene as one of its molecular mechanisms.     

Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice

This paper reports on the effect of GCP-02, a dual activator of the peroxisome proliferator-activated receptors alpha/gamma (PPARalpha/gamma), on glucose and lipid metabolism in insulin-resistant obese mice induced by monosodium glutamate. The mice were divided into four groups on the basis of treatment: control group, rosiglitazone (positive control) (7 micromol/kg), and low- and high-dosage GCP-02 (7 micromol/kg and 3.5 micromol/kg, respectively). Drugs were given orally once a day for 19 days, and mice underwent testing for insulin tolerance, oral glucose tolerance and gluconeogenesis, and plasma cholesterol, triglyceride and free fatty acid levels. Mice were sacrificed, and body length and weight were measured; intraperitoneal adipose, heart and liver weighed; and plasma alanine aminotransferase (ALT) level and aspartate aminotransferase (AST) activity measured. Liver, soleus muscle and myocardium were assayed for glycogen, triglyceride and free fatty acid content and myocardia tested for superoxide dismutase (SOD) activity and malonaldehyde content. RT-PCR revealed expression of insulin receptor substrate 1 and 2 (IRS1, IRS2) and related genes in liver. GCP-02 had a more powerful effect than rosiglitazone on improving insulin sensitivity, ameliorating glucose tolerance, suppressing L-alanine-induced gluconeogenesis, and decreasing plasma levels of cholesterol, triglyceride and free fatty acid. It reduced body weight in control mice, significantly lowered hepatic content of glycogen, triglyceride and free fatty acid and myocardial content of triglyceride, and increased myocardial SOD activity. IRS2 mRNA was down-regulated in control mice but up-regulated by GCP-02. Thus, GCP-02 is a potential candidate for the prevention and therapy of diseases associated with insulin resistance such as type 2 diabetes mellitus and cardiovascular disease.